GlobeNewswire

Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity

Share

Bagsværd, Denmark, 18 June 2020 – Novo Nordisk today announced the headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue (AM833), a phase 2 monotherapy trial and a phase 1 combination trial of AM833 and once-weekly subcutaneous semaglutide 2.4 mg.

AM833 phase 2 monotherapy trial

The 26-week blinded phase 2 monotherapy trial with AM833 investigated safety, tolerability and efficacy for weight management in 706 people with obesity or overweight  with at least one weight-related comorbidity. The patients were randomised to treatment with five different weekly doses of AM833 (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 4.5 mg), liraglutide 3.0 mg or placebo. Approximately 100 people were included in each treatment arm. All treatments were administered in combination with lifestyle intervention therapy. The mean baseline body weight in the trial was 107.4 kg.

The trial reached its primary endpoint by demonstrating a weight loss of 10.8% at week 26 with AM833 at the 4.5 mg dose, compared to a weight loss of 3.0 % with placebo1. The treatment difference was statistically significant. AM833 appeared to have a safe and well-tolerated profile.

AM833 and semaglutide phase 1 combination trial

The 20-week multiple ascending dose phase 1 trial investigated safety, tolerability, pharmacokinetics and weight loss potential of AM833 administrated in combination with semaglutide 2.4 mg in 80 people with obesity or overweight.

After 20 weeks of treatment, participants receiving the highest dose lost an average of 17.1% body weight from a mean baseline body weight of 95.1 kg (secondary end-point)1.

The trial investigated the number of treatment-emergent adverse events (primary end-point) and AM833 was well-tolerated, with the most common adverse events being gastrointestinal disorders including nausea and vomiting, the majority being non-serious and mild or moderate in severity. The level of gastrointestinal disorders observed for the combination of AM833 and semaglutide in the trial was comparable to what is generally seen for glucagon-like peptides-1 (GLP-1) in monotherapy.

"We are encouraged by these impressive results and we look forward to further assessing the efficacy and safety of AM833,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “The phase 1 and 2 data with AM833 for weight management, especially the combination with semaglutide, further strengthen Novo Nordisk’s obesity pipeline and hold potential to close the gap between pharmacotherapy and bariatric surgery” said Mads Krogsgaard Thomsen.

About obesity and AM833 for weight management

Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, chronic kidney disease, non-alcoholic fatty liver disease and cancer.

AM833 is being investigated by Novo Nordisk for weight management in people with obesity and overweight with at least one weight-related comorbidity. AM833 is an acylated long-acting analogue of the human amylin hormone that induces weight loss by reducing energy intake.

About sc semaglutide 2.4 mg for weight management

Once-weekly sc semaglutide 2.4 mg is being investigated by Novo Nordisk as a treatment for adults with obesity. Semaglutide is an analogue of the human GLP-1 hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com
Investors:
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com

Company announcement No 40 / 2020




1 Based on trial product estimand: treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Workday levererar skräddarsydda upplevelser för anställda med hjälp av lösningar för en arbetsmiljö i förändring2.7.2020 10:00:10 CESTPressemelding

Workday erbjuder komplett HR-service genom skapande och hantering av ärenden för snabb och intuitiv lösning Workday Journeys skapar personliga upplevelser för att guida anställda i viktiga situationer STOCKHOLM, Sverige, July 02, 2020 (GLOBE NEWSWIRE) -- Workday Inc. (NASDAQ: WDAY), ledande inom företagsmolnapplikationer för ekonomi och HR, lanserar två nya maskininlärningslösningar inom HR. Workday Help ger intuitiv ärendehantering och Workday Journeys skräddarsydd, individanpassad guidning för anställda i kritiska ögonblick. Applikationerna är de senaste tillskotten inom Workday People Experience där Workday lyfter personalupplevelsen och förenklar arbetet genom maskininlärning. Lösningarna hjälper arbetsgivare att engagera och stötta sina anställda samtidigt som arbetet blir mer personligt och produktivt. Förutom Workday People Experience lanseras även Workday People Analytics, en analysbaserad applikation som identifierar risker och möjligheter inom arbetsgrupper. Informationen ger

Workday People Anaytics levererar automatiserade lösningar för att hjälpa företag att optimera sin arbetskraft i en föränderlig värld2.7.2020 10:00:10 CESTPressemelding

Maskininlärning och augmented analytics ger insikt i och identifierar möjligheter att hjälpa företag att ta sig starkare ur krisen STOCKHOLM, Sverige, July 02, 2020 (GLOBE NEWSWIRE) -- Workday Inc. (NASDAQ: WDAY), ledande inom företagsmolnapplikationer för ekonomi och HR, lanserar Workday People Analytics – en analysbaserad applikation som identifierar risker och möjligheter inom arbetsgrupper och presenterar dessa insikter i ett lättförståeligt story-format. Informationen ger HR- och företagsledare möjlighet att nå starkare resultat – snabbare – genom att fatta bättre beslut gällande sina anställda. Workdays kunder, av vilka mer än 65 procent är Fortune 50-bolag, kan använda Workday People Analytics tillsammans med Workday Human Capital Management (HCM) för att upprätthålla kontinuitet inom företaget och hantera de utmaningar som uppstått i samband med den rådande pandemin. Förutom Workday People Analytics lanseras två lösningar för Workday People Experience som ytterligare hjälper or

Zane Kotāne has been elected as a member of the Management Board of JSC Olainfarm2.7.2020 09:46:00 CESTPress release

Today, the Supervisory Council of JSC Olainfarm has elected Zane Kotāne as a member of the Management Board, who will oversee financial matters. She has significant professional experience in management, finance and governance processes in both listed and state and private companies. “We are pleased that such a high-level specialist is joining the Management Board of Olainfarm. Zane Kotāne has significant experience in the management of both Latvian and international companies. She has in-depth knowledge in areas important to the company, such as financial analysis and planning, attracting investments from the European Union institutions and private investors, as well as internal audits. On behalf of the entire council, we wish her success,” emphasizes Gundars Bērziņš, Chairman of the Supervisory Council of JSC Olainfarm. “It is with great pleasure that I join Olainfarm's international management team and extensive staff to be able to turn a new page in the growth story of Olainfarm to

Publishing of Valmet's Half Year Financial Review January – June 2020 on July 23, 20202.7.2020 09:00:00 CESTPress release

Valmet Oyj’s press release on July 2, 2020 at 10:00 a.m. EET Valmet's Half Year Financial Review for January – June 2020 will be published on Thursday, July 23, 2020 at approximately 3:00 p.m. Finnish time (EET). The stock exchange release and presentation material in English and in Finnish will be available at that time on Valmet's website at www.valmet.com/investors. News conference for analysts, investors and media Valmet will arrange a news conference in English for investment analysts, investors, and media on Thursday, July 23, 2020 at 4:00 p.m. Finnish time (EET). The news conference will be held at Valmet Head Office in Keilaniemi, Keilasatama 5, 02150 Espoo, Finland. President and CEO Pasi Laine and CFO Kari Saarinen will be presenting at the news conference. Webcast The news conference can also be followed through a live webcast at www.valmet.com/webcasts. The live webcast starts at 4:00 p.m. (EET) and a recording of the webcast will be available shortly after the event at the

Cargotec’s January-June 2020 half year financial report to be published on Friday, 17 July 20202.7.2020 08:30:00 CESTPress release

CARGOTEC CORPORATION, PRESS RELEASE, 2 JULY 2020 AT 9.30 AM (EEST) Cargotec’s January-June 2020 half year financial report to be published on Friday, 17 July 2020 Cargotec Corporation will publish its January-June 2020 half year financial report on Friday, 17 July 2020 at approximately 2.00 p.m. EEST. The report will be available at www.cargotec.com after publication. A live international telephone conference for analysts, investors and media, will be arranged on the publishing day at 3:00 p.m. EEST. The event will be held in English. The report will be presented by CEO Mika Vehviläinen and Executive Vice President, CFO Mikko Puolakka. The presentation material will be available at www.cargotec.com by the latest 2:30 p.m. EEST. The telephone conference, during which questions may be presented, can be accessed by registering here. The registration opens 15 minutes prior to the event. The event conferencing system will call the participant on the phone number provided and place the parti

Stolt-Nielsen Limited Reports Unaudited Results For the Second Quarter and First Half of 20202.7.2020 08:25:00 CESTPress release

LONDON, July 2, 2020 – Stolt-Nielsen Limited (Oslo Børs: SNI) today reported unaudited results for the second quarter ended May 31, 2020. The Company reported a second-quarter net profit attributable to shareholders of $3.6 million, with revenue of $503.5 million, compared with a net loss attributable to shareholders of $20.0 million, with revenue of $497.1 million, in the first quarter of 2020. The net loss attributable to shareholders for the first six months was $16.3 million, with revenue of $1,000.5 million, compared with a net profit attributable to shareholders of $11.5 million, with revenue of $1,018.4 million, in the first half of 2019. Highlights for the second quarter of 2020, compared with the first quarter of 2020, were: Net profit from continuing operations amounted to $12.3 million in the second quarter, up from a loss of $19.3 million in the first quarter of 2020.Stolt Tankers reported an operating profit of $20.0 million, up from $4.7 million, mainly reflecting a $12.2